Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident, Computerised tomogram, Thrombosis, X-ray
Clinical narrative: blood clot; stroke, effected his speech,limited ability to communicate,stroke in the left hemisphere; This spontaneous case was reported by a consumer and describes the occurrence of CEREBROVASCULAR ACCIDENT (stroke, effected his speech,limited ability to communicate,stroke in the left hemisphere) and THROMBOSIS (blood clot) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 040A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Aug-2021, the patient experienced CEREBROVASCULAR ACCIDENT (stroke, effected his speech,limited ability to communicate,stroke in the left hemisphere) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced THROMBOSIS (blood clot) (seriousness criteria hospitalization and medically significant). The patient was hospitalized from 27-Aug-2021 to 31-Aug-2021 due to CEREBROVASCULAR ACCIDENT and THROMBOSIS. The patient was treated with CLOPIDOGREL BISULFATE (PLAVIX) for Adverse event, at an unspecified dose and frequency and ACETYLSALICYLIC ACID (BABY ASPIRIN) for Adverse event, at an unspecified dose and frequency. At the time of the report, CEREBROVASCULAR ACCIDENT (stroke, effected his speech, limited ability to communicate, stroke in the left hemisphere) and THROMBOSIS (blood clot) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Computerised tomogram: abnormal (abnormal) showed the blood clot and abnormal (abnormal) stroke in the left hemisphere. On an unknown date, X-ray: abnormal (abnormal) showed the blood clot.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient was diagnosed with a stroke. Prior to going to the emergency room his speech had been effected. He had a limited ability to communicate. He could say simple words, and knows what he wants to say but just can't get it out. He also knows what you're saying to him. This has not changed through today. He also has experienced some short term memory loss. He does not remember any symptoms he experienced prior to going to the emergency room.  Lab data included CT scan, X-ray and lab work which showed the blood clot also receive more CT scans and 2D imaging and stroke in the left hemisphere was detected.  Concomitant medication was not provided.  company comment: This case concerns a  61-year-old, male patient with no relevant medical history, who experienced the unexpected events of stroke and thrombosis. The stroke occurred in the left hemisphere, which was confirmed by CT scans and finding of blood clot, and affected patient's short term memory and patient's ability to speak. The events occurred approximately 4 months after the second dose of . The rechallenge was not applicable. The benefit-risk relationship of Moderna COVID-19 Vaccine / mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a  61-year-old, male patient with no relevant medical history, who experienced the unexpected events of stroke and thrombosis. The stroke occurred in the left hemisphere, which was confirmed by CT scans and finding of blood clot, and affected patient's short term memory and patient's ability to speak. The events occurred approximately 4 months after the second dose of . The rechallenge was not applicable. The benefit-risk relationship of Moderna COVID-19 Vaccine / mRNA-1273 is not affected by this report.